GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InSite Vision Inc (OTCPK:INSV) » Definitions » E10

InSite Vision (InSite Vision) E10 : $-0.08 (As of Jun. 2015)


View and export this data going back to . Start your Free Trial

What is InSite Vision E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

InSite Vision's adjusted earnings per share data for the three months ended in Jun. 2015 was $-0.050. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.08 for the trailing ten years ended in Jun. 2015.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-24), InSite Vision's current stock price is $0.3475. InSite Vision's E10 for the quarter that ended in Jun. 2015 was $-0.08. InSite Vision's Shiller PE Ratio of today is .


InSite Vision E10 Historical Data

The historical data trend for InSite Vision's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InSite Vision E10 Chart

InSite Vision Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.23 -0.19 -0.15 -0.11 -0.09

InSite Vision Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 -0.09 -0.09 -0.08 -0.08

Competitive Comparison of InSite Vision's E10

For the Drug Manufacturers - Specialty & Generic subindustry, InSite Vision's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InSite Vision's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InSite Vision's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where InSite Vision's Shiller PE Ratio falls into.



InSite Vision E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, InSite Vision's adjusted earnings per share data for the three months ended in Jun. 2015 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2015 (Change)*Current CPI (Jun. 2015)
=-0.05/100.6839*100.6839
=-0.050

Current CPI (Jun. 2015) = 100.6839.

InSite Vision Quarterly Data

per share eps CPI Adj_EPS
200509 -0.040 83.876 -0.048
200512 -0.052 83.032 -0.063
200603 -0.060 84.298 -0.072
200606 -0.060 85.606 -0.071
200609 -0.040 85.606 -0.047
200612 -0.031 85.142 -0.037
200703 -0.030 86.640 -0.035
200706 0.020 87.906 0.023
200709 0.040 87.964 0.046
200712 0.025 88.616 0.028
200803 0.010 90.090 0.011
200806 -0.060 92.320 -0.065
200809 -0.080 92.307 -0.087
200812 -0.091 88.697 -0.103
200903 -0.060 89.744 -0.067
200906 -0.040 91.003 -0.044
200909 -0.030 91.120 -0.033
200912 -0.022 91.111 -0.024
201003 -0.030 91.821 -0.033
201006 -0.030 91.962 -0.033
201009 -0.020 92.162 -0.022
201012 -0.020 92.474 -0.022
201103 -0.030 94.283 -0.032
201106 -0.030 95.235 -0.032
201109 0.010 95.727 0.011
201112 -0.025 95.213 -0.026
201203 -0.040 96.783 -0.042
201206 -0.050 96.819 -0.052
201209 0.040 97.633 0.041
201212 -0.014 96.871 -0.015
201303 -0.010 98.209 -0.010
201306 0.090 98.518 0.092
201309 0.000 98.790 0.000
201312 -0.038 98.326 -0.039
201403 -0.040 99.695 -0.040
201406 0.280 100.560 0.280
201409 -0.020 100.428 -0.020
201412 -0.018 99.070 -0.018
201503 -0.010 99.621 -0.010
201506 -0.050 100.684 -0.050

Add all the adjusted EPS together and divide 10 will get our e10.


InSite Vision  (OTCPK:INSV) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


InSite Vision E10 Related Terms

Thank you for viewing the detailed overview of InSite Vision's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


InSite Vision (InSite Vision) Business Description

Traded in Other Exchanges
N/A
Address
InSite Vision Inc was incorporated in 1986 as a California Corporation and reincorporated in Delaware in 1987. The Company is an ophthalmic product development company committed to advancing ophthalmic pharmaceutical products to address unmet eye care needs. The Company completed its initial public offering on October 18, 1993. The Company's current portfolio of ophthalmic pharmaceutical products is based on its proprietary DuraSite drug delivery technology. The Company's DuraSite sustained drug delivery technology is a proven, patented synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a solution, gel or suspension and could be customized for delivering a variety of potential drug candidates. The Company has focused its research, development and commercial support efforts on the following topical products formulated with its DuraSite drug delivery technology. AzaSite or azithromycin ophthalmic solution 1% is a DuraSite formulation of azithromycin developed as a broad spectrum ocular antibiotic and approved by the U.S. Food and Drug Administration in April 2007 to treat bacterial conjunctivitis. Additional indications are being pursued by Inspire Pharmaceuticals for this product. AzaSite was commercially launched in the United States by Inspire Pharmaceuticals in August 2007. DexaSite is a DuraSite formulation of dexamethasone in development for the treatment of ocular inflammation. In November 2011, it initiated a Phase 3 clinical trial for this product candidate in blepharitis and completed patient enrollment in the clinical trial in September 2012. BromSite is a DuraSite formulation of bromfenac in development for the prevention of post-operative inflammation and eye pain. It initiated a Phase 1/2 clinical trial for this product candidate in August 2010 and received positive top-line results from this study in the first quarter of 2011, which demonstrated the efficacy and safety of BromSite. DuraSite 2 is a next-generation enhanced drug delivery system, which is designed to provide a broad platform for developing superior ophthalmic therapeutics. DuraSite 2 is based on the original DuraSite technology, and incorporates a cationic polymer to achieve sustained and enhanced ocular delivery of drugs. ISV-101 is a DuraSite formulation with a low concentration of bromfenac for the treatment of dry eye disease. The Company is subject to regulation by numerous governmental authorities in the United States and other countries.
Executives
Louis Drapeau officer: Vice President and CFO C/O BIOMARIN PHARMACEUTICAL INC., 371 BEL MARIN KEYS BLVD., SUITE 210, NOVATO CA 94949
Brian Levy director
Anthony J Yost director C/O INSITE VISION, INC., 965 ATLANTIC AVENUE, ALAMEDA CA 94501
Timothy Mcinerney director
Craig A Tooman director
Coliseum Capital Management, Llc 10 percent owner 105 ROWAYTON AVENUE, ROWAYTON CT 06853
Timothy P Lynch director 919 NW BOND STREET, SUITE 204, BEND OR 97703
Rick D Anderson director 3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746
Jon S Saxe director FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Francis Wen-hou Chen director 1821 JONES STREET, SAN FRANCISCO CA 94109
Pinto Tv Gp Co Llc 10 percent owner 3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746
Matthew S Crawford 10 percent owner 3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746
Pfizer Inc 10 percent owner 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192

InSite Vision (InSite Vision) Headlines

No Headlines